The Southeast Asia pacemakers market size is expected to reach USD 97.67 million by 2030 and is projected to grow at a CAGR of 5.92% from 2024 to 2030, according to a new report by Grand View Research, Inc. South East Asia is witnessing a significant demographic shift towards an older population. Older individuals are more susceptible to heart-related issues, which increases the need for pacemakers. This aging trend is accelerating the demand for devices that help manage heart rhythm disorders. Moreover, the increasing prevalence of cardiovascular diseases, such as arrhythmias and heart block, is a major driver for the market.

South East Asia Pacemakers Market Report Highlights

The external pacemakers segment held the largest share of more than 50.0% in 2023 due to their widespread use is due to their versatility, ease of application, and the immediate, adjustable support they offer.

The conventional pacemakers segment held the largest share of around 60.0% in 2023. These devices have a long track record of effectiveness in treating bradycardia (slow heart rate) and other arrhythmias.

In 2023, the congestive heart failure (CHF) segment dominated the market, capturing a significant 33.18% share.

Hospitals & cardiac centers held the largest share of 42.27% in 2023. The availability of advanced diagnostic tools, surgical facilities, and post-operative care makes hospitals the preferred setting for pacemaker procedures.

For More Details or Sample Copy please visit link @: South East Asia Pacemakers Market Report

A report from the National Library of Medicine published in April 2024 highlights significant variations in heart failure classifications across Southeast Asia. The INTER-CHF study reveals that 39% of heart failure patients in Malaysia and the Philippines have a reduced left ventricular ejection fraction (LVEF) of less than 40%. Conversely, data from the International REPORT-HF registry shows that in Indonesia, and Thailand, the distribution of heart failure types is 59% HFrEF (heart failure with reduced ejection fraction), 18% HFmrEF (heart failure with mid-range ejection fraction), and 23% HFpEF (heart failure with preserved ejection fraction). Additionally, the NHFR (National Heart Failure Registry of India) reports that HFrEF is the most common classification in South Asia, affecting 65% of patients, followed by HFmrEF at 22% and HFpEF at 13%.

Moreover, government initiatives across Southeast Asia play a crucial role in enhancing access to cardiac pacemakers and improving overall cardiovascular care. The governments are upgrading healthcare infrastructure and modernizing hospitals to include advanced cardiac units, improving access to pacemaker treatments. Initiatives like the Philippines' Universal Health Care (UHC) Law enhance coverage and reduce financial barriers, making advanced cardiac care more accessible to a wider population.

List of major companies in the Southeast Asia Pacemakers Market

Boston Scientific Corporation

Medtronic

BIOTRONIK SE & Co. KG

MicroPort Scientific Corporation

Abbott

Lepu Medical Technology(Beijing)Co.,Ltd.

For Customized reports or Special Pricing please visit @: South East Asia Pacemakers Market Report